Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

In 30 seconds

This post-hoc analysis of a phase 3 trial evaluated the efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis, both with and without prior systemic treatment. The study found that stapokibart significantly improved response rates compared to placebo, with EASI-75 rates of 70.3% vs. 29.1% in treatment-naïve patients at week 16.

Key findings

• EASI-75 response rates were 70.3% for stapokibart vs. 29.1% for placebo in treatment-naïve patients.
• In patients with prior systemic treatment, EASI-75 rates were 61.5% for stapokibart vs. 19.3% for placebo.
• The most common adverse events were infections and infestations, occurring in 61.6% and 70.5% of patients, respectively.
• All patients showed further improvements through week 52.

Why it matters

The findings suggest that stapokibart is effective in improving symptoms of atopic dermatitis regardless of previous systemic treatments, offering a potential new option for managing this condition.